The Case Comprehensive Cancer Center (Case CCC)

What The Case Comprehensive Cancer Center (Case CCC) does

The Case Comprehensive Cancer Center (Case CCC) is an NCI-designated Comprehensive Cancer Center established in 1987 and affiliated with Case Western Reserve University School of Medicine, Cleveland Clinic, and University Hospitals in Cleveland, Ohio. It operates as a research consortium coordinating interdisciplinary cancer research across basic science, translational research, clinical investigation, cancer control, and experimental therapeutics. The center serves cancer patients and survivors by providing access to National Cancer Institute-sponsored clinical trials and research-driven treatment protocols, while also training the next generation of cancer researchers through PhD programs supported by endowed fellowships, including a $2 million endowment established by Linda Leatherbury.

Case CCC's core activities span laboratory research, clinical trials, and computational analysis of biomedical data, delivered through affiliated hospital systems including University Hospitals Cleveland Medical Center and Cleveland Clinic. Notable research outputs include the development of PSMA-1-DOTA, a PSMA-targeted radioligand therapy for advanced prostate cancer demonstrating four times stronger binding to cancer cells with virtually eliminated salivary gland damage compared to current treatments, in collaboration with the Technical University of Munich. The center has also published research in Cancer Letters showing that popular NAD+ precursor supplements (NMN, NR, NAM) may harm cancer patients by promoting chemotherapy resistance, and continues to deliver research findings through peer-reviewed publications and clinical guidelines.

As a non-profit academic institution, Case CCC does not generate revenue through commercial product sales or fee-for-service pricing. Its operations are funded through federal research grants (primarily from the National Cancer Institute and NIH), institutional endowments, and charitable contributions managed under the Case Western Reserve University umbrella. In November 2025, the center announced a strategic partnership with Owkin, Gustave Roussy, and Charité Comprehensive Cancer Center to build Europe's first pan-European agentic infrastructure for biology, signaling an emerging AI-augmented capability for biomedical data structuring and reasoning-driven research.

Name

The Case Comprehensive Cancer Center (Case CCC)

Legal name

Case Western Reserve University

Website

https://case.edu

Company type

Private

Founded year

1826

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

The Case Comprehensive Cancer Center is an NCI-designated cancer research consortium affiliated with Case Western Reserve University, Cleveland Clinic, and University Hospitals, conducting basic, translational, and clinical cancer research and training PhD researchers in Cleveland, Ohio.

Ownership category

akta.pro rank

Product category

Cancer Research

NAICS

Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (62151)

SIC

Services-Health Services (8000), Services-Medical Laboratories (8071)

akta.pro primary industry

Site Data Management Support (EDC/Source/SDV Readiness) (HLAGACAL)

Keywords

• Cancer research programs
• Clinical trials oncology
• Translational cancer research
• Biomedical data analysis
• Experimental therapeutics

Headquarters

HQ city

Cleveland

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Distribution channels1 record

Marketing channels1 record

Core offering

Case CCC is an NCI-designated Comprehensive Cancer Center that operates as a research consortium coordinating interdisciplinary cancer research across Case Western Reserve University, Cleveland Clinic, and University Hospitals. The center delivers basic, translational, and clinical cancer research programs, including access to NCI-sponsored clinical trials, and integrates multidisciplinary teams of researchers, clinicians, and translational scientists to advance cancer treatment, prevention, and training of emerging cancer researchers through PhD programs.

Product overview

The Case Comprehensive Cancer Center (Case CCC) is an NCI-designated comprehensive cancer center that functions as a research consortium rather than a commercial product company. The center coordinates cancer research across Case Western Reserve University and partner institutions. Associated institutional infrastructure includes university library systems (Cleveland Health Sciences Library, Kelvin Smith Library), student information systems, and IT services managed through University Technology (UTech).

Differentiator

Problem solved

Functional benefit

Products and services

• Case Comprehensive Cancer Center Research Programs An interdisciplinary cancer research consortium spanning basic science, clinical research, cancer control, and experimental therapeutics, coordinating research across Case Western Reserve University, Cleveland Clinic, and University Hospitals. Targets cancer researchers, clinicians, and translational scientists.

Quantifiable outcome

• Discovery that popular NAD+ precursor supplements (NMN, NR, NAM) may harm cancer patients by helping cancer cells survive and resist chemotherapy treatment (published in Cancer Letters)
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered flagship and core.

• OwkinflagshipStrategic or Co-development Partner · 18 November 2025Case CCC announced at the Franco-German Summit on Digital Sovereignty in Berlin a landmark initiative to build Europe's first pan-European agentic infrastructure for biology. The partnership combines agentic AI systems with biomedical data structuring to power reasoning models for automating and augmenting biological research stages. Initial focus is on harmonizing and structuring biomedical data across Europe.
• Gustave RoussyflagshipStrategic or Co-development Partner · 18 November 2025European cancer research partner collaborating on the pan-European agentic infrastructure for biology initiative, focused on making biomedical data AI-ready and accelerating drug development across Europe.
• Charité Comprehensive Cancer CenterflagshipStrategic or Co-development Partner · 18 November 2025European comprehensive cancer center partner in the initiative to build Europe's first pan-European agentic infrastructure for biology, demonstrating European digital sovereignty in health AI.
• Technical University of MunichcoreStrategic or Co-development PartnerInternational research collaboration on PSMA-targeted radioligand therapy (PSMA-1-DOTA) for advanced prostate cancer. One human patient was treated at Technical University of Munich in Germany as part of the preclinical and early clinical validation.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Others

• Owkin: AI-for-biology company that is Case CCC's announced partner in the pan-European agentic infrastructure initiative; an enabling technology participant rather than a competing cancer center, but the most relevant ecosystem peer for the AI/biomedical data dimension of Case CCC's strategy.

Direct peers

• Duke Cancer Institute: NCI-designated Comprehensive Cancer Center housed within Duke University, with comparable multidisciplinary cancer research programs and clinical trial infrastructure that parallels Case CCC's mission.
• Roswell Park Comprehensive Cancer Center: One of the original NCI-designated Comprehensive Cancer Centers, founded as a standalone research institution; comparable in research portfolio breadth and clinical trial focus to Case CCC.
• Gustave Roussy: Europe's leading NCI-equivalent Comprehensive Cancer Centre and Case CCC's flagship partner on the pan-European agentic AI initiative; directly comparable in mission, scale, and translational research orientation.
• Abramson Cancer Center (University of Pennsylvania): NCI-designated Comprehensive Cancer Center within an Ivy League academic medical center; comparable consortium-of-schools research footprint to Case CCC's CWRU/Cleveland Clinic/University Hospitals collaboration.
• Dana-Farber Cancer Institute: NCI-designated Comprehensive Cancer Center affiliated with Harvard Medical School conducting basic, translational, and clinical cancer research with multidisciplinary teams — the closest structural and operational analogue to Case CCC's consortium model.
• Fred Hutchinson Cancer Center: NCI-designated Comprehensive Cancer Center integrated with a research university (University of Washington), with strong translational science and clinical trial operations structurally similar to Case CCC's CWRU-affiliated model.
• Charité Comprehensive Cancer Center: Berlin-based Comprehensive Cancer Center partner of Case CCC on the pan-European agentic AI infrastructure initiative, providing direct peer comparability on AI-driven biomedical data harmonization efforts.
• Memorial Sloan Kettering Cancer Center: One of the original NCI-designated Comprehensive Cancer Centers focused on translational research and clinical trials, with deep bench-to-bedside pipelines that closely mirror Case CCC's mission and research scope.
• University of Texas MD Anderson Cancer Center: The largest NCI-designated Comprehensive Cancer Center by research funding and patient volume; provides a benchmark for the operational scale and translational commercialization Case CCC's consortium model aspires to achieve.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/caseccc
• YouTubeyoutube.com/user/case
• Facebookfacebook.com/CaseCCC
• Instagraminstagram.com/cwru
• LinkedInlinkedin.com/company/case-western-reserve-university

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Case Comprehensive Cancer Center (Case CCC)